

Scientific and Clinical Advances Advisory Committee (SCAAC) – matters arising

Monday 10 June 2019, 1.00pm – 4.00pm

Date and item	Action	Responsibility	Due date	Progress to date
04/02/2019, 4.4	The Chief Executive and the HFEA Chair will consider whether the HFEA should release a statement on genome editing.	HFEA	Complete	The regulatory framework in the UK does not allow for genetically edited offspring and therefore has not been raised as an area of concern that the HFEA need to respond to. The HFEA will continue to monitor the area of genome editing.
04/02/2019, 4.10 & 4.11	Executive to review expertise in the Committee	Dina Halai, Scientific Policy Manager	Complete	Committee membership has been reviewed and new members have joined.
19/06/2018, 3.9	Circulate a Word file of the ICSI literature review with a view of editing the paper for publication in a scientific journal	Dina Halai, Scientific Policy Manager	Ongoing	The Committee Chair is working on editing for publication following SCAAC comments. HFEA to update the literature review.
02/05/2018, 5.9	Follow up with Prof Macklon for more information relating to intrauterine culture and develop a strategy for reviewing patient information	Dina Halai, Scientific Policy Manager	Ongoing	According to the HFEA's Standard Operative Procedure, due to the lack of sufficient data and concerns raised about the safety of the device, the HFEA have asked the SCAAC Chair and Deputy Chair on behalf of the SCAAC, to formally recommend whether intrauterine culture should

remain as an authorised novel process or be considered by the SAC for de-authorisation.

02/05/2018,
5.9

The authorised processes list will be reviewed to ensure processes are listed correctly

Dina Halai,
Scientific Policy
Manager

Ongoing

The Executive's Policy and Compliance have agreed that there should be a separate category for novel processes in the authorised process list and will work with the communications team to update the categorisation.